Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Barclays Maintains Overweight on Immunogen, Raises Price Target to $9

Barclays Maintains Overweight on Immunogen, Raises Price Target to $9

Barclays analyst Peter Lawson maintains Immunogen (NASDAQ:IMGN) with a Overweight and raises the price target from $8 to $9.

November 15, 2022

1 minute read

Barclays analyst Peter Lawson maintains Immunogen (NASDAQ:IMGN) with a Overweight and raises the price target from $8 to $9.

JP Morgan Downgrades Axon Enterprise to Neutral, Announces $224 Price Target

March 2, 7:30 AM

JP Morgan analyst Paul Chung downgrades Axon Enterprise (NASDAQ:AXON) from Overweight to Neutral and announces $224 price target.

February 13, 12:00 PM

In the latest quarter, 5 analysts provided ratings for Louisiana-Pacific (NYSE:LPX), showcasing a mix of bullish and bearish…

January 30, 2:00 PM

Arcus Biosciences (NYSE:RCUS) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from…

November 1, 9:13 AM

Another rare sealed box of the original iPhone has fetched a whopping $133,435 at an auction. It was part of the original iPhone 4GB batch.